Table 1 Baseline clinical characteristics of the study patients
From: Prognostic value of CT-based radiomics in grade 1–2 pancreatic neuroendocrine tumors
Variable | Development set | Test set | P value |
|---|---|---|---|
Number of patients | 441 | 159 | |
Age (years)* | 53.0 ± 12.3 | 55.9 ± 12.5 | 0.011 |
Sex | 0.186 | ||
Men | 184 (41.7) | 76 (47.8) | |
Women | 257 (58.3) | 83 (52.2) | |
Tumor size | 0.061 | ||
< 2 cm | 180 (40.8) | 82 (51.6) | |
2–4 cm | 167 (37.9) | 54 (34.0) | |
> 4 cm | 89 (20.2) | 23 (14.5) | |
2019 WHO grade | 0.749 | ||
Grade 1 | 285 (64.6) | 105 (66.0) | |
Grade 2 | 156 (35.4) | 54 (34.0) | |
8th AJCC stage | 0.327 | ||
I | 175 (39.7) | 76 (47.8) | |
II | 215 (48.8) | 61 (38.4) | |
III | 39 (8.8) | 19 (11.9) | |
IV | 12 (2.7) | 3 (1.9) | |
Follow-up data | |||
Follow-up (months)† | 68.3 (38.9, 107.9) | 59.7 (32.2, 101.0) | 0.017 |
Recurrence | 58 (13.2) | 14 (8.8) | 0.148 |
Death | 35 (7.9) | 12 (7.5) | 0.876 |